Five (10%) had luminal A, nineteen (40%) had luminal B, five (10%) had HER2-enriched, twenty-one (40%) had triple-negative and one patient had an atypical molecular subtype of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.